Literature DB >> 12061483

Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach.

Bruno Spire1, Ségolène Duran, Marc Souville, Catherine Leport, François Raffi, Jean-Paul Moatti.   

Abstract

To-date, most socio-behavioural research about HTV-infected patients' adherence to highly active antiretroviral therapies (HAART) has been based on cross-sectional studies. The French APROCO cohort gave us the opportunity to conjointly analyse the relationships between short-term adherence to HAART and HIV-infected patients' characteristics before initiation of treatment on the one hand, factors related to patients' subjective experience with HAART on the other hand. At the fourth-month follow-up visit (M4) after first prescription of HAART (M0), 26.7% of our sample of 445 patients self-reported non-adherence behaviour. Some patients' characteristics at M0 (younger age, poor housing conditions, lack of social support, and problems of adherence with previous antiretroviral regimens) were related to non-adherence at M4 in multivariate analysis. Non-adherence at M4 was, however, also related to the evolutions that affected a number of factors between M0 and M4: levels of depression, symptoms associated with treatment side effects, perception of individual state of health, beliefs towards effectiveness and toxicity of HAART. increases in alcohol and tobacco consumption, as well as contacts with other physicians than hospital HAART prescribers. Our prospective study brings additional evidence that even short-term non-adherence cannot be reliably predicted on the sole basis of a few a priori patient characteristics that clinicians could easily identify before initiation of HAART. It suggests that a dynamic approach to adherence, continuously monitoring the impact of experience with HAART on patients' daily lives, is needed for improving management of HIV/AIDS care.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12061483     DOI: 10.1016/s0277-9536(01)00125-3

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  72 in total

1.  Antiretroviral adherence during pregnancy and postpartum in Latin America.

Authors:  Regis Kreitchmann; D Robert Harris; Fabiana Kakehasi; Jessica E Haberer; Pedro Cahn; Marcelo Losso; Elizabete Teles; Jose H Pilotto; Cristina B Hofer; Jennifer S Read
Journal:  AIDS Patient Care STDS       Date:  2012-06-04       Impact factor: 5.078

2.  Trauma, dissociation, and antiretroviral adherence among persons living with HIV/AIDS.

Authors:  Alex S Keuroghlian; Charles S Kamen; Eric Neri; Susanne Lee; Rhianon Liu; Cheryl Gore-Felton
Journal:  J Psychiatr Res       Date:  2011-06-01       Impact factor: 4.791

3.  Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.

Authors:  X Panhard; C Goujard; M Legrand; A M Taburet; B Diquet; F Mentré
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

Review 4.  Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management.

Authors:  Jane M Simoni; Ann E Kurth; Cynthia R Pearson; David W Pantalone; Joseph O Merrill; Pamela A Frick
Journal:  AIDS Behav       Date:  2006-05

5.  A Social Problem-Solving Model of Adherence to HIV Medications.

Authors:  Mallory O Johnson; Timothy R Elliott; Torsten B Neilands; Stephen F Morin; Margaret A Chesney
Journal:  Health Psychol       Date:  2006-05       Impact factor: 4.267

6.  Differences in adherence and motivation to HIV therapy--two independent assessments in 1998 and 2002.

Authors:  Björn Södergård; Margit Halvarsson; Stefan Lindbäck; Anders Sönnerborg; Mary P Tully; Asa Kettis Lindblad
Journal:  Pharm World Sci       Date:  2006-10-26

7.  Alcohol consumption among HIV-infected women: impact on time to antiretroviral therapy and survival.

Authors:  Robyn C Neblett; Heidi E Hutton; Bryan Lau; Mary E McCaul; Richard D Moore; Geetanjali Chander
Journal:  J Womens Health (Larchmt)       Date:  2011-01-31       Impact factor: 2.681

8.  Toxoplasmic encephalitis in AIDS-patients before and after the introduction of highly active antiretroviral therapy (HAART).

Authors:  T R Kiderlen; O Liesenfeld; D Schürmann; T Schneider
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-15       Impact factor: 3.267

9.  Sero-positive African Americans' beliefs about alcohol and their impact on anti-retroviral adherence.

Authors:  Andrea Sankar; Tracy Wunderlich; Stewart Neufeld; Mark Luborsky
Journal:  AIDS Behav       Date:  2007-03

10.  HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use.

Authors:  Geetanjali Chander; Seth Himelhoch; John A Fleishman; James Hellinger; Paul Gaist; Richard D Moore; Kelly A Gebo
Journal:  AIDS Care       Date:  2009-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.